HEALTHIER CHINA THROUGH INNOVATION

Established in 1999, the R&D-Based Pharmaceutical Association Committee (RDPAC), representing 46 leading multinational pharmaceutical companies with R&D capabilities, is a committee under the China Association of Enterprises with Foreign Investment (CAEFI), which in turn reports to the Ministry of Commerce of the People's Republic of China.

NEWS

RDPAC Announces New Chair and Vice-Chairs of the 2024-2025 Executive Committee

October 23, 2023
RDPAC officially announces the new Chair and Vice-Chairs of the Executive Committee for the 2024-2025 term.

RDPAC Announces New Executive Committee Members for 2024-2025

September 28, 2023
RDPAC is pleased to announce the list of members for the new executive committee for the term 2024-2025.

RDPAC was Invited to Participate in the NMPA's "2023 ICH in China: Progress and Outlook Symposium"

October 07, 2023
NMPA held 2023 ICH in China: Progress and Outlook Symposium in Beijing on September 12.

PUBLICATIONS

THE FACES OF
INNOVATION

MEETING THE CHALLENGE OF CANCER

Cancer, refers to all malignant tumors, with biological characteristics such as abnormal cell differentiation and proliferation, loss of growth control, invasiveness and metastasis. It is one of the leading causes of death worldwide, led more than 22,000 deaths every day globally. In China, about 10,000 patients are diagnosed with cancer every day, that is, about 7 patients with cancer are diagnosed every minute ...

POLICY PILLARS OF PHARMACEUTICAL INNOVATION

FOR A HEALTHIER CHINA

Discuss how to both improve patient access to innovative drugs and promote sustainabledevelopment of the medical insurance system to achieve a win-win situation.

DEEPENING THE DRUG INNOVATION ECOSYSTEM REFORM – A PLAN TO DESIGN AND BUILD CHINA’S CLINICAL RESEARCH SYSTEM

Health is the common aspiration of all mankind, and a healthy China constitutes an integral part of the “China Dream”.